Loncastuximab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loncastuximab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loncastuximab Today - Breaking & Trending Today

Fixed-Duration Data Foreshadow Earlier Use of Loncastuximab Tesirine in Relapsed/Refractory DLBCL

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma. ....

United States , Michal Kwiatek , Mohamed Zaki , Society Of Hematologic Oncology , Centrum Medyczne Pratia Poznan , Ann Arbor , Hematologic Oncology , Society Of Hematologic Oncology Annual Meeting Soho , Non Hodgkin Lymphoma , Relapsed Refractory Diffuse Largeb Cell Lymphoma , Phase 3 Lotis 5 Trial ,

Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta ....

United States , New Jersey , United Kingdom , City Of , Lausanne Biop , Anders Ullman , Prnewswire Sobi , Company On Twitter , European Commission , Drug Administration , Sobi Investor Relations Team , Committee For Orphan Medicinal Products , European Union , Head Of Research Development , Medicinal Products , Human Use , European Medicines Agency , Medical Affairs , Chief Medical Officer , Ameet Mallik , Chief Executive Officer , Orphan Medicinal Products , San Francisco Bay Area , Cancer Research United Kingdom , North America , Middle East ,

ADC Therapeutics SA: ADC Therapeutics and Sobi Announce ZYNLONTA (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Approval decision expected in 4Q 2022 ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European ....

United Kingdom , United States , New Jersey , City Of , Amanda Loshbaugh , Lausanne Biop , Mary Ann Ondish , Anders Ullman , John Radford , Eugenia Litz , Company On Twitter , Mitsubishi Tanabe Pharma Corporation , European Commission , University Of Manchester , Drug Administration , Foundation Trust In Manchester , Exchange Commission , European Medicines Agency , Overland Pharmaceuticals , Committee For Medicinal Products Human Use , Head Of Research Development , Swedish Orphan Biovitrum , Medicinal Products , Human Use , Ameet Mallik , Chief Executive Officer ,

Loncastuximab tesirine receives positive CHMP opinion for the treatment of relapsed or refractory diffuse large B-cell lymphoma: Swedish Orphan Biovitrum AB

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ Sobi and ADC Therapeutics SA today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted ....

United Kingdom , United States , New Jersey , City Of , Lausanne Biop , Anders Ullman , John Radford , Thomas Kudsk Larsen , Prnewswire Sobi , Company On Twitter , European Commission , University Of Manchester , Drug Administration , Sobi Investor Relations Team , Foundation Trust In Manchester , European Medicines Agency , Committee For Medicinal Products Human Use , Head Of Research Development , Medicinal Products , Human Use , Chief Medical Officer , Ameet Mallik , Chief Executive Officer , Medical Oncology , San Francisco Bay Area , Cancer Research United Kingdom ,

Swedish Orphan Biovitrum AB: Sobi to license loncastuximab tesirine from ADC Therapeutics

Agreement augments Sobi's strategic presence in haematology with new orphan medicine STOCKHOLM, July 8, 2022 /PRNewswire/ Sobi today announced an exclusive license agreement with ADC ....

United States , New Jersey , City Of , United Kingdom , Lausanne Biop , Thomas Kudsk Larsen , Prnewswire Sobi , Guido Oelkers , Company On Twitter , Drug Administration , Sobi Investor Relations Team , San Francisco Bay Area , North America , Middle East , Sobi Media ,